Table 2. Baseline characteristics and demographics of patients included in the post-authorization safety analysis (n = 2,397).
| Characteristic | |
|---|---|
| Patients, n | 2,397 |
| Gender, n (%) | |
| Male | 1,117 (46.6) |
| Female | 1,280 (53.4) |
| Mean age, years (range) | 60.4 (3 – 94) |
| 2 – 12 years, n (%) | 8 (0.3) |
| 13 – 17 years, n (%) | 18 (0.8) |
| 18 – 43 years, n (%) | 372 (15.5) |
| 44 – 68 years, n (%) | 1,077 (44.9) |
| > 68 years, n (%) | 922 (38.5) |
| Diagnosis, n | |
| PID | 363 |
| SID | 1,368 |
| ITP | 253 |
| Guillain-Barré syndrome | 6 |
| CIDP | 58 |
| MMN | 17 |
| Myasthenia gravis | 16 |
| Multiple sclerosis | 163 |
| Dermatomyositis | 10 |
| Polymyositis | 12 |
| Pemphigus vulgaris | 3 |
| Other | 128 |
CIDP = chronic inflammatory demyelinating polyneuropathy; ITP = immune thrombocytopenia; MMN = multifocal motor neuropathy; PID = primary immunodeficiency; SID = secondary immunodeficiency.